Biotech Strategy Blog

Commentary on Science, Innovation & New Products

About Pieter Droppert

Here are my most recent posts

Posts by Pieter Droppert

Juno Therapeutics takes on Penn in dispute over St Jude Chimeric Antigen Receptor Patent

The Inquirer yesterday reported on Philly.com that start-up Juno Therapeutics (Juno) are now in control of a legal dispute between St Jude Children’s Hospital (St Jude) and the University of Pennsylvania (Penn) over chimeric antigen receptor (CAR) intellectual property that contributed to the development of CTL019, licensed by Penn to Novartis. Thanks to @lomu_j for sharing this news on Twitter.

Leave a comment